CytoDyn successfully completes preclinical colon cancer treatment studies

CytoDyn Inc (OTCMKTS:CYDY) announced strong preclinical results Friday from a series of completed studies of its colon cancer treatment, leronlimab.

The studies found that leronlimab was able to suppress colon carcinoma tumor growth in mice genetically modified to have a human immune system.

The drug works by blocking CCR5, a cellular receptor associated with tumor growth and metastasis. The studies, conducted at the Cleveland Clinic, indicated that leronlimab was capable of stifling tumor growth in both high and low CCR5 expression tumors.

The results suggest a possible role for the human immune system in tumor control and a use for leronlimab as a new therapy for tumors expressing CCR5.

READ: CytoDyn inks exclusive licensing pact with IncellDX to supply non-commercial grade PRO 140 antibody

CytoDyn CEO Nader Pourhassan commented: “The results that we are announcing today provide a potential, significant opportunity in oncology. We are encouraged by the pipeline of opportunities leronlimab continues to create, with potentially accelerated path to approval in several cancer indications.”

Leronlimab was previously granted Fast Track designation by the Food and Drug Administration for two other purposes: the treatment of HIV in combination with the “cocktail” known as highly active antiretroviral therapy, and for metastatic triple-negative breast cancer, a rare variety which doesn’t respond to some treatments.

Fast Track designation is designed to expedite the review process of a drug that would meet a serious unmet medical need.

All told, leronlimab has successfully completed nine clinical trials in more than 800 people.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors